Lessons learned from randomizing infants to marine oil-supplemented formulas in nutrition trials.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 7965451.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effect of n-3 fatty acid intake on docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6) status, growth, retinal physiology, visual acuity, and development (Bayley Mental Developmental Index and Fagan Infantest) has been evaluated in infants randomized to a marine oil source of docosahexaenoic acid or to standard infant formula. This article will focus on the lessons learned in conducting these randomized trials--issues related to design, implementation, and interpretation. By addressing these issues it is hoped that several general concepts related to nutrition studies in infants can be explored that might prove useful to others who undertake clinical nutrition trials in general, and trials with n-3 and n-6 fatty acids in particular.
Medical subject headings
- Arachidonic Acid
- Child Development
- Docosahexaenoic Acids
- Fatty Acids, Omega-3
- Fatty Acids, Unsaturated
- Fish Oils
- Food, Fortified
- Infant Food
- Infant Nutritional Physiological Phenomena
- Infant, Premature